Drug Trial Radar · NCT06226766
JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
11
Actual
Start
Jan 18, 2024
Primary completion
Jul 31, 2025
Study completion Jul 31, 2025
Sponsor
- Lead sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter, first-in-human, Phase I/II (dose escalation and dose expansion) study to evaluate the safety, tolerability, PK, immunogenicity and efficacy of JSKN033 in patients with advanced unresectable or metastatic solid malignant tumors that are expected to be HER2 expression (IHC ≥ 1+).
Conditions
- Advanced Solid Tumor
Interventions
JSKN033 InjectionDrug
JSKN033 is a combination drug product comprised of JSKN003 and envafolimab for subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), assessed by CTCAE V5.0Time frame: Postdose of last participant up to 1 year
- RP2D( recommend Phase II dose)Time frame: Postdose of last participant up to 1 year
- DLTs (Dose-limiting toxicities)Time frame: Baseline up to 21 days after the first dose
- Objective Response Rate (ORR) Following Treatment With JSKN033 in Participants With Advanced Solid Malignant TumorsTime frame: From 6 weeks postdose of last participant up to 1 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Scientia Clinical Research
Randwick, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.